Lumena Files For $75 Million IPO To Forward Liver Disease Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech investment momentum may have slowed recently, but the San Diego biotech is hoping the IPO window remains open. The company is developing a compound shelved by Pfizer to address high cholesterol; LUM001 currently is in Phase II for a set of cholestatic liver diseases.
You may also be interested in...
Lumena Pharmaceuticals Takes $23M To Fight Rare Liver Disease
The San Diego start-up will use its Series A round to continue development on a pair of drugs for cholestatic liver disease. Once studied by Pfizer and Sanofi to fight high cholesterol but shelved years ago as statins proved more effective, the drugs show promise in orphan indications.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.